Related Experiment Videos
p53: a target for new anticancer drugs or a target for old drugs?
1CRC Dept of Medical Oncology, Beatson Laboratories, Glasgow, UK.
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
Journal of the National Cancer Institute·1995
Health education intervention strategies: recommendations for future research.
Health education quarterly·1995
Immunological detection of Bacteroides fragilis in clinical samples.
Journal of medical microbiology·1995
Trauma center designation: initial impact on trauma-related mortality.
The Journal of trauma·1995
Difficulty accepting lifestyle limitations after the abrupt onset of end-stage renal disease.
Advances in renal replacement therapy·1995
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.
The Journal of experimental medicine·2026
Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC.
Molecular cancer therapeutics·2026
Toward Fit-for-Purpose Data for Drug Assessment in Non-small Cell Lung Cancer: A Core Dataset.
Clinical pharmacology and therapeutics·2026
Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer.
Molecular pharmaceutics·2026